FDA Clears Palatin's IND Application For Phase 2 Study Of Bremelanotide Co-Administered With Tirzepatide For Obesity, The Phase 2 Study Is Expected To Start By Mid-2024, With Topline Data Results By The End Of 2024
美国食品药品管理局批准了帕拉丁对布雷美拉诺肽与替西帕肽共同施用治疗肥胖症的2期研究的IND申请,该2期研究预计将于2024年中期开始,主要数据结果将于2024年底公布